IP Library Granted Patent US 8,178,334
Granted Patent B2
US 8,178,334 · App. 13/226,891 · Granted May 15, 2012

Variant form of urate oxidase and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,334
App. No.
13/226,891
Granted
May 15, 2012
Kind
B2
Abstract

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.

Claims (6)

1. An isolated nucleic acid comprising a nucleic acid sequence which encodes a uricase selected from the group consisting of: a uricase comprising the amino acid sequence of position 8 through position 287 of SEQ ID NO. 12; a uricase comprising the amino acid sequence of position 8 through position 287 of SEQ ID NO. 13; a uricase comprising the amino acid sequence of position 8 through position 287 of SEQ ID NO. 12 further comprising an amino terminal amino acid, wherein the amino terminal amino acid is alanine, glycine, proline, serine, or threonine; and a uricase comprising the amino acid sequence of position 8 through position 287 of SEQ ID NO. 12 further comprising an amino terminal amino acid, wherein the amino terminal amino acid is methionine.

2. The isolated nucleic acid of claim 1 , wherein the nucleic acid sequence is operatively linked to a heterologous promoter.

3. The nucleic acid of claim 2 , wherein the promoter is the osmB promoter.

4. A nucleic acid vector comprising the nucleic acid of claim 2 .

5. A host cell comprising the vector of claim 4 .

6. A method for producing a uricase comprising the steps of culturing the host cell of claim 5 under conditions such that the nucleic acid sequence is expressed by the host cell and isolating the expressed uricase.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SELLER'S NAME AND EXECUTION DATE PREVIOUSLY RECORDED ON REEL 032675 FRAME 0936. ASSIGNOR(S) HEREBY CONFIRMS THE SELLER'S NAME SHOULD READ SAVIENT PHARMA HOLDINGS, INC. AND THE EXECUTION DATE FOR BOTH PARTIES SHOULD READ 01/09/2014. Recorded Jun 16, 2023
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 064009/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2022
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 062191/0611 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 061805 FRAME 0076. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 1, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062073/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC
Reel/Frame 061805/0076 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0049 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2014
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 032675/0936 →
SECURITY AGREEMENT Recorded Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
SECURITY AGREEMENT Recorded Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 028363 FRAME 0040. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
SECURITY AGREEMENT Recorded Jun 12, 2012
From: SAVIENT PHARMACEUTICALS, INC.
To: MORGAN STANLEY SENIOR FUNDING INC.
Reel/Frame 028363/0040 →